Long-Term Efficacy Data Continues to Support Larotrectinib Use for Tumor With NTRK Fusions

Retrieved on: 2021-06-09 13:07:30

Tags for this article:

Orphan drugs

Medicine

Medical terminology

Drugs

Larotrectinib

Progression-free survival

Clinical medicine

Click the tags to see associated articles and topics

Long-Term Efficacy Data Continues to Support Larotrectinib Use for Tumor With NTRK Fusions. View article details on hiswai:

Excerpt

Results of an integrated dataset analysis across 3 studies of the TRK inhibitor larotrectinib (Vitrakvi) in patients with NTRK fusion–positive cancers show ...

Article found on: www.cancernetwork.com

View Original Article